論文

査読有り
2014年8月

[Analysis of factors influencing the occurrence of infusion reaction after initial treatment with rituximab].

Gan to kagaku ryoho. Cancer & chemotherapy
  • Masahiro Yasuda
  • Tomoya Tachi
  • Michi Umeda
  • Kazumasa Usui
  • Katsuhiro Nagaya
  • Tomohiro Osawa
  • Atsushi Ichihashi
  • Hideko Goto
  • Senji Kasahara
  • Takeshi Takahashi
  • Hitomi Teramachi
  • Chitoshi Goto
  • 全て表示

41
8
開始ページ
975
終了ページ
9
記述言語
日本語
掲載種別
研究論文(学術雑誌)

We investigated factors influencing the occurrence of infusion reactions after initial treatment with rituximab. We included patients who were administered rituximab for the treatment of B-cell non-Hodgkin's lymphoma at the Gifu Municipal Hospital Hematology from February 2010 to March 2013. Fifty-one patients were included; their median age was 72(44-87)years, and 31 were men and 20 were women. We defined the index of infusion reaction as the maximal change in body temperature within 24 hours from the administration of rituximab and evaluated the correlation with change in body temperature and each factor, and differences of change in body temperature between the upper and lower groups divided by standard value of each factor by using the t test without correspondence. The "2,000 U/mL or less group"of soluble interleukin-2 receptor(sIL- 2R)levels and the "over 2,000 U/mL group"showed significant different(p=0.014). The "double value or less group"of a standard value(211 IU/L)and "over double value group"showed significantly different lactate dehydrogenase(LDH)levels (p=0.017). The "lower limit or less group"of the standard value(men: 13 g/dL, women: 12 g/dL)and the "over lower limit group"showed significantly different hemoglobin(Hb)levels(p=0.020). In conclusion, the levels of sIL-2R, LDH, and Hb may predict the occurrence of infusion reaction after the initial administration of rituximab in patients with B-cell non-Hodgkin's lymphoma.

リンク情報
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/25132029
ID情報
  • ISSN : 0385-0684
  • PubMed ID : 25132029

エクスポート
BibTeX RIS